GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » Price-to-Free-Cash-Flow

Sera Prognostics (Sera Prognostics) Price-to-Free-Cash-Flow : N/A (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Price-to-Free-Cash-Flow?

As of today (2024-04-29), Sera Prognostics's share price is $10.75. Sera Prognostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.88. Hence, Sera Prognostics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Sera Prognostics's Price-to-Free-Cash-Flow or its related term are showing as below:

SERA's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.56
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Sera Prognostics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.22. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.88.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.40% per year.

During the past 5 years, Sera Prognostics's highest 3-Year average Free Cash Flow per Share Growth Rate was 2.40% per year. The lowest was -0.40% per year. And the median was 1.00% per year.


Sera Prognostics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Sera Prognostics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Price-to-Free-Cash-Flow Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Sera Prognostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sera Prognostics's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Sera Prognostics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sera Prognostics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Price-to-Free-Cash-Flow falls into.



Sera Prognostics Price-to-Free-Cash-Flow Calculation

Sera Prognostics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=10.75/-0.876
=N/A

Sera Prognostics's Share Price of today is $10.75.
Sera Prognostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Sera Prognostics  (NAS:SERA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Sera Prognostics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics (Sera Prognostics) Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.
Executives
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc 10 percent owner 239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin officer: VP OF Q/R & HIPPA PRIV. OFF C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare officer: Chief Commercial Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109